AYTU BIOPHARMA, INC Advertising Expense
AYTU BIOPHARMA, INC (AYTU) reported Advertising Expense of $4.90 million for the 12-month period ending 2024-06-30, per its 10-K filed 2024-09-26.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AdvertisingExpense · last filed 2024-09-26
- AYTU BIOPHARMA, INC advertising expense for fiscal 2024 was $4.90M, a 71.51% decline from fiscal 2023.
- AYTU BIOPHARMA, INC advertising expense for fiscal 2023 was $17.20M, a 26.47% increase from fiscal 2022.
- AYTU BIOPHARMA, INC advertising expense for fiscal 2022 was $13.60M, a 10.53% decline from fiscal 2021.
- AYTU BIOPHARMA, INC advertising expense for fiscal 2021 was $15.20M, a 223.40% increase from fiscal 2020.
| Period end | Advertising Expense 12 month | Advertising Expense 12 month as first filed |
|---|---|---|
| 2024-06-30 | $4.90M 10-K · filed 2024-09-26 | |
| 2023-06-30 | $17.20M 10-K · filed 2024-09-26 | $11.10M 10-K · filed 2023-10-12 |
| 2022-06-30 | $13.60M 10-K · filed 2023-10-12 | |
| 2021-06-30 | $15.20M 10-K · filed 2022-09-27 | |
| 2020-06-30 | $4.70M 10-K · filed 2021-09-28 | |
| 2019-06-30 | $0.00 10-K · filed 2020-10-06 | |
| 2012-08-31 | $1.38K 10-K · filed 2012-11-29 | |
| 2011-08-31 | $916.00 10-K · filed 2012-11-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |